Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
TRANSCRIPT OF ANALYST AND INVESTOR CALL31-10-2022
31-10-2022
Buy Eris Lifesciences; target of Rs 850: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 850 in its research report dated October 25, 2022.25-10-2022
Eris Lifesciences Ltd - 540596 - AUDIO RECORDING OF THE EARNINGS CONFERENCE CALL ON THE UNAUDITED CONSOLIDATED AND STANDALONE FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2022
Dear Sir/Madam, In accordance with the applicable requirements and regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable Regulations, we hereby inform you that the Audio Recording of the Earnings Conference Call in connection with the Unaudited Consolidated and Standalone Financial Results of the Company for the quarter and half year ended 30th September 2022, held on 20th October 2022, is available on the website of the Company and can be accessed through the following link: Link: https://eris.co.in/financials/ (File name: Q2 FY23-Earnings Call Recording)20-10-2022
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to the requirement of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the investor presentation made by the Company.20-10-2022
Eris Lifesciences Ltd - 540596 - Board Meeting Outcome for OUTCOME OF THE BOARD MEETING
We hereby inform that the Board of Directors of the Company at their meeting held today i.e. 20 October 2022 has, inter alia, transacted the following business: ? Approved and took on record the limited reviewed Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September 2022. The duly signed Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September 2022 are enclosed herewith. ? The Board considered the re-classification request received from M/s. Shah & Co. The Board reviewed the application received and formed a view that the said request does not prejudice the interests of the Company and its stakeholders in any manner. The Board, therefore, approved the proposal and approved its reference to the stock exchanges for their approval in terms of Regulation 31A of Listing Regulations. The meeting of the Board of Directors commenced at 11:00 A.M. and concluded at 12:30 P.M.20-10-2022
Eris Lifesciences Ltd - 540596 - Results-Financial Results For The Quarter And Half Year Ended 30Th September, 2022
We hereby inform that the Board of Directors of the Company at their meeting held today i.e. 20 October 2022 has, inter alia, transacted the following business: ? Approved and took on record the limited reviewed Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September 2022. The duly signed Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September 2022 are enclosed herewith. ? The Board considered the re-classification request received from M/s. Shah & Co. The Board reviewed the application received and formed a view that the said request does not prejudice the interests of the Company and its stakeholders in any manner. The Board, therefore, approved the proposal and approved its reference to the stock exchanges for their approval in terms of Regulation 31A of Listing Regulations.20-10-2022
Eris Lifesciences Ltd - 540596 - Reply To The Clarification Sought On Increase In Volume Of The Shares Of The Company
This is with reference to your email dated October 13, 2022 seeking clarification for significant increase in the Volume of our Security across the Exchanges. In this regards, we wish to inform you that all the material information / announcement that may have bearing on the operations / performance of the Company which include all the necessary disclosures in accordance with regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and under insider trading regulation, have always been disclosed by the Company within stipulated time and the same is available in public domain. There is no pending information or announcements which have a bearing on increase in price/volume of security of the Company.13-10-2022
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is further to our letter dated 11 October 2022 intimating about the date of the Board of Directors Meeting to, inter alia, consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended 30 September 2022. We wish to inform that pursuant to regulation 30 and other applicable regulations, if any, of the SEBI LODR, 2015 the Company will hold a conference call for analysts and investors on Thursday, 20 October 2022. The details of the said call are attached herewith and also available on Company's website.11-10-2022
Eris Lifesciences Ltd - 540596 - Board Meeting Intimation for Consideration And Approval Of The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter Ended 30 September 2022.
Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2022 ,inter alia, to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended 30 September 2022. Further, as informed by us vide letter dated 28 September 2022, the trading window has been already closed from 01 October 2022 and will remain closed till 48 hours after the declaration of financial results of the Company pursuant to SEBI [Prohibition of Insider Trading] Regulations, 2015 and Policy on 'Code of Conduct to Regulate, Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company for the purpose of Board Meeting.11-10-2022
Eris Lifesciences Ltd - 540596 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
CERTIFICATE UNDER REGULATION 74(5) OF SEBI (DEPOSITORIES AND PARTICIPANTS) REGULATIONS, 2018 FOR THE QUARTER ENDED SEPTEMBER 202207-10-2022